Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
Masaud Shah, Bilal Ahmad, Sangdun Choi, Hyun Goo Woo
Abstract
V-loop of RBD possibly hinders neutralization of SARS-CoV-2 by anti-SARS-CoV mAbs. In addition, we identified unique and structurally conserved conformational-epitopes on RBDs, which can be potential therapeutic targets. Collectively, we provide new insights into the mechanisms underlying the high infectivity of SARS-CoV-2 and development of effective neutralizing agents.
Topics & Concepts
NeutralizationInfectivityCoronavirusVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Monoclonal antibodyEpitopeGlycoproteinMutationPlasma protein bindingBinding siteBiologyAntibodyCoronavirus disease 2019 (COVID-19)VirusChemistryMolecular biologyGeneGeneticsMedicineBiochemistryDiseasePathologyInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies